{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:27:16Z","timestamp":1792517236170,"version":"4.5.0"},"reference-count":45,"publisher":"American Association for Cancer Research (AACR)","issue":"7","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>The tumor microenvironment (TME) is difficult to model in an in vivo cancer research setting. This study leveraged intratumor microdosing using comparative in vivo oncology (CIVO) with spatial profiling to evaluate the effects of the stimulator of interferon genes agonist dazostinag, alone or with chemotherapy, on cellular responses within the native TME of intact human tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>This phase 0 study enrolled adult patients with head and neck squamous cell carcinoma (HNSCC) planned for surgical intervention. Intratumoral microdose injections of dazostinag (maximum dose: 1.68 \u03bcg in a 0.05 mg\/mL solution), alone or combined with various chemotherapies, were delivered via CIVO to tumors 24, 48, 72, or 96 hours prior to resection. Each tumor sample was prepared for analysis using IHC and ISH. Analysis of the microdosed tumors using the GeoMx Digital Spatial Profiler and CosMx Spatial Molecular Imager was performed in one patient.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Type 1 IFN signaling was induced with dazostinag alone and in combination with chemotherapy from multiple cell types within the TME, including immune cells. Dazostinag also shifted the polarization of macrophages from an immune-suppressive phenotype to a proinflammatory phenotype at 24 hours after injection. Enrichment of cytotoxic T cells was observed in regions of localized dazostinag exposure, coinciding with increased chemokine (CXCL9) expression. Based on cleaved caspase-3, an apoptosis marker, dazostinag plus chemotherapy increased cellular apoptosis relative to either drug alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Utilizing CIVO and spatial profiling technology, dazostinag alone and combined with chemotherapy promoted an early proinflammatory response and enhanced chemotherapy-mediated cell death in the native TME of intact human HNSCC tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>The CIVO approach demonstrates that dazostinag alone and combined with chemotherapy promotes both proapoptotic and early proinflammatory responses in the native TME of intact human HNSCC tumors, providing clinical evidence for an on-target mechanism of action and rationale for further clinical investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0314","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T11:34:03Z","timestamp":1752752043000},"page":"1243-1255","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["<i>In Situ<\/i>\n                    Proinflammatory Effects of Dazostinag Alone or with Chemotherapy on the Tumor Microenvironment of Patients with Head and Neck Squamous Cell Carcinoma"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5041-1882","authenticated-orcid":false,"given":"Richard C.","family":"Gregory","sequence":"first","affiliation":[{"name":"1Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9156-4423","authenticated-orcid":false,"given":"Neil","family":"Lineberry","sequence":"additional","affiliation":[{"name":"1Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6419-3719","authenticated-orcid":false,"given":"Alex","family":"Parent","sequence":"additional","affiliation":[{"name":"1Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2148-1643","authenticated-orcid":false,"given":"Karthik","family":"Rajasekaran","sequence":"additional","affiliation":[{"name":"2University of Pennsylvania, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9389-2332","authenticated-orcid":false,"given":"Thomas J.","family":"Ow","sequence":"additional","affiliation":[{"name":"3Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7386-318X","authenticated-orcid":false,"given":"Cherie-Ann","family":"Nathan","sequence":"additional","affiliation":[{"name":"4Louisiana State University Health, Shreveport, Louisiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5635-3388","authenticated-orcid":false,"given":"Beryl A.","family":"Hatton","sequence":"additional","affiliation":[{"name":"5Presage Biosciences, Inc., Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4592-1773","authenticated-orcid":false,"given":"Wendy","family":"Jenkins","sequence":"additional","affiliation":[{"name":"5Presage Biosciences, Inc., Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0177-7896","authenticated-orcid":false,"given":"Marc","family":"Grenley","sequence":"additional","affiliation":[{"name":"5Presage Biosciences, Inc., Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9365-3612","authenticated-orcid":false,"given":"Connor","family":"Burns","sequence":"additional","affiliation":[{"name":"5Presage Biosciences, Inc., Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0899-304X","authenticated-orcid":false,"given":"Angela","family":"Merrell","sequence":"additional","affiliation":[{"name":"5Presage Biosciences, Inc., Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3044-6136","authenticated-orcid":false,"given":"Jason P.","family":"Frazier","sequence":"additional","affiliation":[{"name":"5Presage Biosciences, Inc., Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7620-0003","authenticated-orcid":false,"given":"Jonathan M.J.","family":"Derry","sequence":"additional","affiliation":[{"name":"5Presage Biosciences, Inc., Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3325-082X","authenticated-orcid":false,"given":"Emily","family":"Beirne","sequence":"additional","affiliation":[{"name":"5Presage Biosciences, Inc., Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4913-5803","authenticated-orcid":false,"given":"Richard A.","family":"Klinghoffer","sequence":"additional","affiliation":[{"name":"5Presage Biosciences, Inc., Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"2025073002573845900_bib1","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1158\/2767-9764.CRC-21-0161","article-title":"TAK-676: a novel stimulator of interferon genes (STING) agonist promoting durable IFN-dependent antitumor immunity in preclinical studies","volume":"2","author":"Carideo Cunniff","year":"2022","journal-title":"Cancer Res Commun"},{"key":"2025073002573845900_bib2","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1158\/2326-6066.CIR-22-0017","article-title":"Activation of tumor-cell STING primes NK-cell therapy","volume":"10","author":"Knelson","year":"2022","journal-title":"Cancer Immunol Res"},{"issue":"Suppl 15","key":"2025073002573845900_bib3","doi-asserted-by":"crossref","first-page":"TPS2670","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS2670","article-title":"A phase 1 dose-escalation study of intravenously (IV) administered TAK-676, a novel STING agonist, alone and in combination with pembrolizumab in patients (pts) with advanced or metastatic solid tumors","volume":"39","author":"Falchook","year":"2021","journal-title":"J Clin Oncol"},{"issue":"Suppl 16","key":"2025073002573845900_bib4","doi-asserted-by":"crossref","first-page":"TPS2698","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS2698","article-title":"TAK-676 in combination with pembrolizumab after radiation therapy in patients (pts) with advanced non\u2013small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), or squamous-cell carcinoma of the head and neck (SCCHN): phase 1 study design","volume":"40","author":"Cooper","year":"2022","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"2025073002573845900_bib5","doi-asserted-by":"crossref","first-page":"S625","DOI":"10.1016\/j.annonc.2023.09.2168","article-title":"1029P Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced or metastatic solid tumors: preliminary safety, PK\/PD, and anti-tumor activity in a phase I dose escalation study supporting a recommended dose for expansion (RDE)","volume":"34","author":"Olszanski","year":"2023","journal-title":"Ann Oncol"},{"issue":"Suppl 2","key":"2025073002573845900_bib6","first-page":"A882","article-title":"778 Phase 1b study of dazostinag plus pembrolizumab after hypofractionated radiotherapy in patients with non-small-cell lung cancer, triple-negative breast cancer, or head and neck squamous-cell carcinoma","volume":"12","author":"Cooper","year":"2024","journal-title":"J ImmunoTher Cancer"},{"issue":"Suppl 2","key":"2025073002573845900_bib7","doi-asserted-by":"crossref","first-page":"S678","DOI":"10.1016\/j.annonc.2024.08.1055","article-title":"996MO Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced\/metastatic solid tumors: data from phase I dose escalation","volume":"35","author":"Luke","year":"2024","journal-title":"Ann Oncol"},{"key":"2025073002573845900_bib8","doi-asserted-by":"crossref","first-page":"873","DOI":"10.6004\/jnccn.2020.0031","article-title":"Head and neck cancers, version 2.2020, NCCN clinical Practice guidelines in oncology","volume":"18","author":"Pfister","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"2025073002573845900_bib9","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"2025073002573845900_bib10","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1158\/2326-6066.CIR-16-0104","article-title":"Established T cell-inflamed tumors rejected after adaptive resistance was reversed by combination STING activation and PD-1 pathway blockade","volume":"4","author":"Moore","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"2025073002573845900_bib11","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1038\/s41467-021-22572-8","article-title":"STING enhances cell death through regulation of reactive oxygen species and DNA damage","volume":"12","author":"Hayman","year":"2021","journal-title":"Nat Commun"},{"key":"2025073002573845900_bib12","doi-asserted-by":"crossref","first-page":"e0187532","DOI":"10.1371\/journal.pone.0187532","article-title":"STING expression and response to treatment with STING ligands in premalignant and malignant disease","volume":"12","author":"Baird","year":"2017","journal-title":"PLoS One"},{"key":"2025073002573845900_bib13","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1172\/JCI129497","article-title":"HPV16 drives cancer immune escape via NLRX1-mediated degradation of STING","volume":"130","author":"Luo","year":"2020","journal-title":"J Clin Invest"},{"key":"2025073002573845900_bib14","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1158\/2767-9764.CRC-23-0299","article-title":"Differential regulation of the STING pathway in human papillomavirus\u2013positive and -negative head and neck cancers","volume":"4","author":"Saulters","year":"2024","journal-title":"Cancer Res Commun"},{"key":"2025073002573845900_bib15","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"2025073002573845900_bib16","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth","volume":"41","author":"de Visser","year":"2023","journal-title":"Cancer Cell"},{"key":"2025073002573845900_bib17","doi-asserted-by":"crossref","first-page":"107753","DOI":"10.1016\/j.pharmthera.2020.107753","article-title":"Tumor microenvironment as a therapeutic target in cancer","volume":"221","author":"Xiao","year":"2021","journal-title":"Pharmacol Ther"},{"key":"2025073002573845900_bib18","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41568-022-00547-1","article-title":"A timeline of tumour-associated macrophage biology","volume":"23","author":"Cassetta","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"2025073002573845900_bib19","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","article-title":"Tumor-associated macrophages: from mechanisms to therapy","volume":"41","author":"Noy","year":"2014","journal-title":"Immunity"},{"key":"2025073002573845900_bib20","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep"},{"key":"2025073002573845900_bib21","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature12626","article-title":"Influence of tumour micro-environment heterogeneity on therapeutic response","volume":"501","author":"Junttila","year":"2013","journal-title":"Nature"},{"key":"2025073002573845900_bib22","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","article-title":"Estimation of clinical trial success rates and related parameters","volume":"20","author":"Wong","year":"2019","journal-title":"Biostatistics"},{"key":"2025073002573845900_bib23","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nrd4090","article-title":"Trial watch: phase II and phase III attrition rates 2011\u20132012","volume":"12","author":"Arrowsmith","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"2025073002573845900_bib24","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1158\/1078-0432.CCR-20-0614","article-title":"Multiplexed evaluation of microdosed antineoplastic agents in situ in the tumor microenvironment of patients with soft tissue sarcoma","volume":"26","author":"Gundle","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2025073002573845900_bib25","doi-asserted-by":"crossref","first-page":"284ra58","DOI":"10.1126\/scitranslmed.aaa7489","article-title":"A technology platform to assess multiple cancer agents simultaneously within a patient\u2019s tumor","volume":"7","author":"Klinghoffer","year":"2015","journal-title":"Sci Transl Med"},{"key":"2025073002573845900_bib26","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1158\/1078-0432.CCR-23-0827","article-title":"Trackable intratumor microdosing and spatial profiling provide early insights into activity of investigational agents in the intact tumor microenvironment","volume":"29","author":"Derry","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2025073002573845900_bib27","article-title":"Guidance for industry, investigators, and reviewers. Exploratory IND studies","author":"US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research","year":"2006"},{"key":"2025073002573845900_bib28","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1186\/s12935-021-02089-2","article-title":"New insights into M1\/M2 macrophages: key modulators in cancer progression","volume":"21","author":"Liu","year":"2021","journal-title":"Cancer Cell Int"},{"key":"2025073002573845900_bib29","doi-asserted-by":"crossref","first-page":"722916","DOI":"10.3389\/fonc.2021.722916","article-title":"CCL2: an important mediator between tumor cells and host cells in tumor microenvironment","volume":"11","author":"Jin","year":"2021","journal-title":"Front Oncol"},{"key":"2025073002573845900_bib30","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 challenges in cancer immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"key":"2025073002573845900_bib31","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3390\/cancers12030690","article-title":"Comparative molecular analysis of cancer behavior cultured in vitro, in vivo, and ex vivo","volume":"12","author":"Hum","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2025073002573845900_bib32","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3390\/cancers15010139","article-title":"Role of patient-derived models of cancer in translational oncology","volume":"15","author":"Idrisova","year":"2022","journal-title":"Cancers"},{"key":"2025073002573845900_bib33","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41416-019-0495-5","article-title":"The role of mouse tumour models in the discovery and development of anticancer drugs","volume":"121","author":"Ireson","year":"2019","journal-title":"Br J Cancer"},{"key":"2025073002573845900_bib34","doi-asserted-by":"crossref","first-page":"6033","DOI":"10.3390\/cancers13236033","article-title":"Pre-clinical in vitro models used in cancer research: results of a worldwide survey","volume":"13","author":"Martinez-Pacheco","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025073002573845900_bib35","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1158\/1078-0432.CCR-20-1452","article-title":"Bridging the translational divide in oncology: in vivo testing of chemo-sensitivity","volume":"26","author":"Sleijfer","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2025073002573845900_bib36","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1126\/science.ade2292","article-title":"CXCL9:SPP1 macrophage polarity identifies a network of cellular programs that control human cancers","volume":"381","author":"Bill","year":"2023","journal-title":"Science"},{"key":"2025073002573845900_bib37","doi-asserted-by":"crossref","first-page":"e2309026","DOI":"10.1002\/advs.202309026","article-title":"Pharmacological polarization of tumor-associated macrophages toward a CXCL9 antitumor phenotype","volume":"11","author":"Enbergs","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"2025073002573845900_bib38","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/s41416-022-01763-0","article-title":"CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer","volume":"126","author":"Seitz","year":"2022","journal-title":"Br J Cancer"},{"key":"2025073002573845900_bib39","doi-asserted-by":"crossref","first-page":"1077780","DOI":"10.3389\/fonc.2023.1077780","article-title":"CXCL9 correlates with antitumor immunity and is predictive of a favorable prognosis in uterine corpus endometrial carcinoma","volume":"13","author":"Xue","year":"2023","journal-title":"Front Oncol"},{"key":"2025073002573845900_bib40","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","article-title":"Mechanisms controlling PD-L1 expression in cancer","volume":"76","author":"Cha","year":"2019","journal-title":"Mol Cell"},{"key":"2025073002573845900_bib41","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1038\/s41388-018-0581-9","article-title":"Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles","volume":"38","author":"Grabosch","year":"2019","journal-title":"Oncogene"},{"key":"2025073002573845900_bib42","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/PPO.0000000000000303","article-title":"Mechanisms of resistance to PD-1 and PD-L1 blockade","volume":"24","author":"Nowicki","year":"2018","journal-title":"Cancer J"},{"key":"2025073002573845900_bib43","doi-asserted-by":"crossref","first-page":"1758835920937902","DOI":"10.1177\/1758835920937902","article-title":"Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies","volume":"12","author":"Walsh","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"Suppl 16","key":"2025073002573845900_bib44","doi-asserted-by":"crossref","first-page":"6020","DOI":"10.1200\/JCO.2025.43.16_suppl.6020","article-title":"Dose expansion data from iintune-1, a phase 1\/2 study of the STING agonist dazostinag plus pembrolizumab as first-line (1L), in patients with recurrent\/metastatic squamous cell carcinoma of the head and neck (RM-SCCHN)","author":"Fayette","year":"2025","journal-title":"J Clin Oncol"},{"key":"2025073002573845900_bib45","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.7326\/M22-1460","article-title":"Good publication practice (GPP) guidelines for company-sponsored biomedical research: 2022 update","volume":"175","author":"DeTora","year":"2022","journal-title":"Ann Intern Med"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0314\/3631488\/crc-25-0314.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/7\/1243\/3637684\/crc-25-0314.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/7\/1243\/3637684\/crc-25-0314.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T06:57:51Z","timestamp":1753858671000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/5\/7\/1243\/763890\/In-Situ-Proinflammatory-Effects-of-Dazostinag"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0314","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.29672764","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29672731","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29672752","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29672755","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29672722","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29672743","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29672776","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29672770","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29672740","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29672773","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29672761","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29672728","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29672749","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29672719","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29672746","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29672779","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29672734","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29672767","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29672737","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29672758","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29672725","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.7955881","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]}}}